Autoimmune thyroid diseases and Th17/Treg lymphocytes.

Area of Science:

• Immunology
• Endocrinology
• Microbiome research

Background:

• Thyroid autoimmunity and autoimmune thyroid disease (AITD) severity are linked to an imbalance between T helper 17 (Th17) cells and regulatory T cells (Tregs).
• Mechanisms include genetic factors, aberrant Th17/Treg-related molecules, and gut dysbiosis.
• Existing research highlights the critical role of Th17/Treg cell dynamics in AITD pathogenesis.

Purpose of the Study:

• To explore the underlying mechanisms of Th17/Treg imbalance in AITD.
• To review novel therapeutic strategies aimed at restoring Th17/Treg equilibrium for AITD treatment.
• To assess the clinical potential of these emerging therapies.

Main Methods:

• Review of existing research on Th17/Treg cell function in AITD.
• Analysis of genetic, molecular, and microbiome-related factors contributing to imbalance.
• Evaluation of therapeutic approaches targeting intracellular signaling, cytokines, and transcription factors.

Main Results:

• The imbalance of Th17 and Tregs is a key factor in thyroid autoimmunity.
• Therapeutic strategies focus on regulating signaling pathways, neutralizing cytokines, and manipulating transcription factors.
• Several agents are being investigated for their potential in AITD treatment.

Conclusions:

• Restoring the Th17/Treg balance is a promising therapeutic avenue for AITD.
• Despite challenges, the clinical outlook for these novel treatments is positive.
• Further research and clinical application are expected to advance AITD management.